A mid-sized pharmaceutical company specializing in generic injectable drugs faced mounting regulatory scrutiny and supply instability at the same time. Several inspections had highlighted weaknesses in oversight of contract manufacturers and raw material suppliers. In parallel, disruptions at a key active pharmaceutical ingredient producer had caused production delays and backorders. Leadership recognized that a fragmented approach to supplier oversight was no longer tenable. A comprehensive supply chain and vendor risk management transformation was initiated, with Radner’s team leading the design and implementation.
The context was demanding. Regulatory agencies expected robust, documented control over the entire supply chain, including third-party manufacturers and critical raw material sources. Patients and healthcare providers depended on consistent availability of life-saving medications. Any significant disruption or quality incident could trigger not only financial loss but also serious reputational damage. Radner’s team approached the engagement with a dual focus: strengthening compliance and enhancing operational resilience, recognizing that these objectives were deeply interconnected in the pharmaceutical sector.
The first phase centered on mapping the extended supply chain. Radner’s team compiled a comprehensive inventory of contract manufacturing organizations, raw material suppliers, packaging vendors and logistics partners. For each entity, the team documented products or services provided, regulatory status, inspection history and existing quality agreements. This exercise revealed gaps, such as outdated agreements, incomplete visibility into sub-suppliers and inconsistent documentation of change controls. It also highlighted dependencies on a small number of critical API suppliers.
With the landscape clarified, Radner’s team developed a structured risk assessment framework aligned with regulatory expectations. The framework evaluated suppliers across dimensions including GMP compliance, data integrity, quality system maturity, capacity reliability, geopolitical exposure and business continuity planning. Each dimension was supported by specific indicators, such as inspection outcomes, deviation trends, audit findings and responsiveness to corrective actions. Suppliers were scored and categorized into risk tiers, providing a transparent basis for prioritization.
Quality, regulatory affairs, procurement and supply chain teams were engaged in validating and refining the risk assessments. Workshops allowed subject matter experts to challenge assumptions, provide context for historical issues and identify emerging concerns. For example, regulatory affairs highlighted upcoming changes in guidelines that could affect certain excipient suppliers. Supply chain teams pointed out where lead times were already stretched and where alternative sources were limited. Radner’s team integrated these insights into a dynamic risk model that could be updated as new information emerged.
One of the most critical findings involved a contract manufacturer responsible for several high-volume injectable products. While past inspections had been satisfactory, recent internal audits revealed weaknesses in data integrity controls and documentation practices. Radner’s team conducted a focused assessment, reviewing batch records, electronic systems and deviation management processes. The assessment confirmed that while product quality had not been compromised, the control environment needed strengthening to meet evolving regulatory expectations. This created urgency for a structured remediation plan.
Radner’s team worked with the pharmaceutical company and the contract manufacturer to design a joint remediation and risk mitigation program. The program included enhancements to electronic batch record systems, stricter access controls, improved training on data integrity and more rigorous internal audit schedules. Clear milestones and metrics were defined, and progress was monitored through regular governance meetings. This collaborative approach allowed the company to preserve a critical supply relationship while addressing regulatory concerns proactively.
Beyond individual suppliers, Radner’s team focused on system-level improvements. Quality agreements were standardized and updated to reflect current regulatory expectations and internal policies. These agreements specified responsibilities for change control, deviation reporting, stability studies and validation activities. They also defined expectations for regulatory inspection readiness and information sharing. Procurement and quality teams were trained to ensure that new agreements were consistently applied and that legacy contracts were brought into alignment over time.
Supply continuity planning was another major pillar of the transformation. For each critical product, Radner’s team facilitated structured risk reviews that examined the entire supply chain from raw materials to finished goods distribution. These reviews identified single points of failure, such as sole-source APIs or specialized packaging components. Where feasible, alternative suppliers were identified and qualified, even if initial volumes were small. In cases where alternatives were not immediately available, contingency plans were developed, including inventory strategies and prioritized allocation protocols for potential shortages.
Technology enablement focused on integrating quality and supply chain data to support ongoing vendor risk management. Radner’s team helped configure dashboards that combined supplier performance metrics, audit findings, deviation trends and supply reliability indicators. These dashboards allowed cross-functional teams to monitor risk signals in near real time. Alerts were set up for events such as critical deviations, regulatory warning letters or significant delays. This integration reduced the risk of important information being siloed within individual functions.
To embed the new approach, governance structures were strengthened. A cross-functional supplier risk committee was established, including representatives from quality, regulatory affairs, procurement, supply chain and finance. The committee met regularly to review high-risk suppliers, approve remediation plans and make decisions on supplier qualification or disqualification. Radner’s team supported the committee with structured agendas, decision frameworks and documentation templates. This formal governance ensured that supplier-related decisions were transparent, consistent and well-documented for regulatory purposes.
Training and culture change were essential components of the engagement. Radner’s team developed targeted training modules on topics such as risk-based supplier qualification, data integrity expectations, and the interplay between quality and supply continuity. These sessions were delivered to internal teams as well as, in some cases, to key suppliers. The goal was to create a shared understanding of expectations and to encourage a mindset where vendor risk management was seen as a core part of delivering safe, reliable medicines rather than an administrative burden.
As the program progressed, tangible improvements became evident. Regulatory inspections began to reflect the strengthened oversight, with inspectors noting improvements in supplier management processes and documentation. The number of supplier-related deviations decreased, and when issues did arise, they were detected and addressed more quickly. Supply disruptions were mitigated more effectively due to clearer contingency plans and better communication with suppliers. Radner’s team helped the company track these outcomes and present them in a way that resonated with both internal stakeholders and regulators.
One notable success story involved a potential disruption at a key API supplier due to an unexpected regulatory inspection. Thanks to the enhanced monitoring and communication protocols, the pharmaceutical company received early warning of potential delays. Contingency plans were activated, including temporary adjustments to production schedules and prioritized allocation of existing inventory. The company also engaged with healthcare providers to manage expectations and avoid sudden stockouts. As a result, patient impact was minimized, and the situation was resolved without major escalation.
Over time, the pharmaceutical company leveraged its strengthened vendor risk management capabilities as a competitive advantage. When bidding for contracts with hospitals and healthcare systems, it could demonstrate robust oversight of its supply chain, supported by documented processes and performance data. This reassured customers concerned about drug shortages and quality issues. Internally, the improved stability allowed for more predictable planning and reduced the need for costly last-minute interventions.
Radner’s team gradually transitioned from intensive implementation support to periodic advisory engagements. The company established an internal center of expertise responsible for maintaining the risk framework, updating policies and coordinating major supplier assessments. Lessons learned from the initial focus on injectables were extended to other product lines, including oral solids and specialty formulations. The risk model was updated periodically to reflect changes in regulations, market dynamics and internal priorities.
By the conclusion of the transformation, the pharmaceutical company had moved from a reactive, fragmented approach to a proactive, integrated model of supply chain and vendor risk management. Compliance risks were better controlled, and supply continuity was more robust. The company had built a foundation that could support future growth, new product launches and expansion into additional markets. Radner’s team demonstrated that in a highly regulated industry, disciplined third-party quality and risk oversight is not only a regulatory necessity but also a strategic enabler of reliable patient care and sustainable business performance.
